ME/CFS AUSTRALIA (SA) INC
Registered Charity 698
PO Box 28,
South Australia 5007
North Terrace House,
19 North Terrace,
Hackney, SA, 5069
1300 128 339
ME/CFS Australia (SA) Inc supports the needs of sufferers of Myalgic Encephalomyelitis, Chronic Fatigue Syndrome and related illnesses. We do this by providing services and information to members.
ME/CFS Australia (SA) Inc aims to keep members informed of various research projects, diets, medications, therapies, news items, etc. All communication, both verbal and written, is merely to disseminate information and not to make recommendations or directives.
Unless otherwise stated, the views expressed on this Web site are not necessarily the official views of the Society or its Committee and are not simply an endorsement of products or services.
Cholecalciferol Injection May Help Fibromyalgia
Monday 13 July 2015
Cholecalciferol injection may reduce fatigue, musculoskeletal pain in patients with fibromyalgia
Patients with fibromyalgia may have improvements in fatigue and musculoskeletal pain by increasing vitamin D levels through monthly, intramuscular cholecalciferol injection, according to recently presented research.
A study of 73 patients with rheumatoid arthritis (RA), 102 patients with osteoarthritis (OA) and 40 patients with fibromyalgia (FM) who did not supplement with vitamin D was conducted. Baseline vitamin D levels were measured, and a VAS was used to assess musculoskeletal pain and fatigue. Patients received 200,000 IU cholecalciferol every 4 weeks through an intramuscular injection for a total of three injections during the study period. VAS and biochemical response were measured at baseline, 12 and 24 weeks.
Patients with FM (77.5%) had significantly lower levels of vitamin D compared with patients with RA (64.4%) and OA (23.5%) at baseline. Levels of vitamin D were negatively correlated with VAS for pain and fatigue in all three diseases, but also with the Disease Activity Score in 28 joints in patients with RA and with the Fibromyalgia Impact Questionnaire (FIQ) score in patients with FM.
At week 12, mean serum 25-OHD levels were significantly higher in the 102 patients with 25-OHD deficiency at baseline. After receiving cholecalciferol injections, patients from each group showed significant decreases from baseline in VAS for pain and fatigue at weeks 12 and 24; however, the effects were greater in patients with FM compared with patients with RA or OA between weeks 12 and 24, according to the researchers. – by Shirley Pulawski
Choi BY, et al. Paper #THU0307. Presented at: European League Against Rheumatism Annual European Congress of Rheumatology; June 10-13, 2015; Rome.
Disclosure: The researchers report no relevant financial disclosures.
The above, with comments and more photos, originally appeared here.
blog comments powered by Disqus